HOLX - ホロジック （Hologic Inc.） ホロジックHOLXのチャート
HOLXの企業情報
| symbol | HOLx |
|---|---|
| 会社名 | Hologic Inc （ホロジック） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Medical Electronics |
| 業種 | 先端医療機器_テクノロジ― 医療関連（Health Care） |
| 概要 | 事業概要 ホロジック(Hologic Inc.)は女性のヘルスケアニーズに応える診断製品、医療用画像処理システム及び外科製品の開発・製造・提供に従事する会社。同社は診断、乳房健康、産婦人科(GYN)手術及び骨格健康という4つの事業部門を運営する。同社の診断製品は、APTIMAアッセイ系製品、ThinPrepシステム、ラピッド胎児性フィブロネクチン及びProcleix血液スクリーニングアッセイを含む。同社はB型肝炎ウイルス(HBV)、C型肝炎ウイルス(HCV)及びヒト免疫不全ウイルス-1(HIV-1)の定量のためのウイルス負荷のアッセイを提供する。乳房健康の製品は、デジタル式乳房撮影システム、コンピュータ支援診断(CAD)及び乳房生検のガイダンスシステムなどの乳房画像と関連する製品・アクセサリーを含む。GYN手術製品は、NovaSure子宮内膜アブレーションシステムとMyoSure子宮筋腫切除システムを含む。骨格健康部門は、Discovery・Horizon X線骨密度測定装置とミニCアーム撮像システムを提供する。 ホロジックは米国の医療機器製造会社。遺伝子関連試薬、医薬品、診断薬、医療機器、理化学機器などの研究開発・製造・販売を手掛ける。主な製品は｢NovaSure｣子宮内膜アブレ―ションシステムや｢MyoSure｣子宮筋腫除去システム、ホライゾン骨濃度計など。本社はマサチュ―セッツ州ベッドフォ―ド。 driven by our ethos, the science of sure, we’re a diverse, dedicated, creative team that develops, markets and services some of the most innovative and accurate diagnostic imaging systems and surgical products on the planet. while we’re focused and passionate about our work, we never forget that what we’re really doing is giving people greater confidence and peace of mind in their diagnosis—enabling healthier lives, everywhere, every day. connect with us at hologic.com, on facebook at facebook.com/hologicjobs, and on twitter @hologic_jobs. |
| 本社所在地 | 250 Campus Drive Marlborough MA 01752 USA |
| 代表者氏名 | Stephen P. MacMillan スティーブン・P・マクミラン |
| 代表者役職名 | Chairman of the Board President Chief Executive Officer 取締役会長兼最高経営責任者（CEO） |
| 電話番号 | +1 508-263-2900 |
| 設立年月日 | 31321 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 1990年 |
| 従業員数 | 6233人 |
| url | www.hologic.com |
| nasdaq_url | https://www.nasdaq.com/symbol/holx |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） 999.60000 |
| 終値（lastsale） | 40.67 |
| 時価総額（marketcap） | 11067232974.56 |
| 時価総額 | 時価総額（百万ドル） 11110.77 |
| 売上高 | 売上高（百万ドル） 3207.3 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 13805.57 |
| 当期純利益 | 当期純利益（百万ドル） -433.60000 |
| 決算概要 | 決算概要 BRIEF: For the nine months ended 30 June 2018 Hologic Inc. revenues increased 7% to $2.4B. Net loss before extraordinary items totaled $516.3M vs. income of $672.8M. Revenues reflect Medical Aesthetics segment increase from $126M to $268.5M Breast Health segment increase of 7% to $896M Skeltal Health segment increase of 4% to $66.8M Europe segment increase of 27% to $284.4M United States segment increase of 2% to $1.8B. |
HOLXのテクニカル分析
HOLXのニュース
Illumina names Hologic CEO as chair, elects Edwards CFO to board 2023/06/02 14:32:37 Seeking Alpha
Illumina''s (ILMN) board has elected Hologic (HOLX) CEO Stephen MacMillan as its new non-executive chair and Edwards Lifesciences (EW) CFO Scott Ullem as an independent director.
Illumina board appoints Hologic CEO as non-exec chairman 2023/06/02 11:56:28 Investing.com
https://www.investing.com/news/stock-market-news/illumina-board-appoints-hologic-ceo-as-nonexec-chairman-3097094
Hologic receives FDA clearance for Panther Fusion to test COVID-19 2023/05/19 13:05:52 Seeking Alpha
Hologic (HOLX) said it had received U.S. FDA clearance for Panther Fusion SARS-CoV-2/Flu A/B/RSV assayThe assay detects and differentiates major respiratory viruses including…
Hologic Granted FDA Clearance of Panther Fusion SARS-CoV-2/Flu A/B/RSV Assay 2023/05/19 12:10:02 Investing.com
https://www.investing.com/news/assorted/hologic-granted-fda-clearance-of-panther-fusion-sarscov2flu-abrsv-assay-432SI-3086658
iCAD, Hologic gain after update on breast screening guidelines 2023/05/09 16:13:32 Seeking Alpha
iCAD (ICAD) and Hologic (HOLX) recorded sharp gains on Tuesday after the U.S. Preventive Services Task Force proposed changes to breast cancer screening. Read more here.
Non-Invasive Aesthetic Treatment Global Market Report 2022 2022/09/09 11:59:00 GlobeNewswire
Major players in the non-invasive aesthetic treatment market are Galderma S. A. , Allergen, Cutera Inc. , Alma Lasers, Cynosure, Solta Medical, Syneron Candela, Lumenis, Merz Pharma, Hologic Inc, Revance Therapeutics Inc. Major players in the non-invasive aesthetic treatment market are Galderma S. A. , Allergen, Cutera Inc. , Alma Lasers, Cynosure, Solta Medical, Syneron Candela, Lumenis, Merz Pharma, Hologic Inc, Revance Therapeutics Inc.
Global Medical Imaging Market Size to Grow by USD 35.8 Billion | Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, And Trends 2022/09/05 17:01:30 Benzinga
WASHINGTON, Sept. 05, 2022 (GLOBE NEWSWIRE) -- The market is expected to grow as a result of factors such as the rising incidence of lifestyle-related diseases, the rising demand for early detection tools, technological advancements to speed up turnaround times, increased government investment & reimbursement initiatives, and the expansion of new facilities by market players in developing countries. Additionally, the emphasis on early diagnosis has increased due to the rising prevalence of chronic diseases like cardiovascular, neurologic problems, and other conditions, as well as the realignment of healthcare systems. For example, the Centers for Disease Control and Prevention (CDC) estimate that 18.2 million adults in the United States alone suffer from coronary artery disease (CAD) each year. Diagnostic imaging is the process of obtaining visual representations of a body''s interior for both diagnostic and therapeutic reasons using various imaging techniques. This covers a variety of modalities that are used to take pictures of the human body for the purpose of diagnosing and treating disorders and, as a result, is essential to improving general health.
Hologic Stock: Underappreciated Gem; Bright Future (NASDAQ:HOLX) 2022/09/02 03:03:24 Seeking Alpha
Hologic''s business has remained strong despite a slowdown in COVID-19-related business. Read why I will be initiating a long position in HOLX stock.
Hologic Inc. (NASDAQ: HOLX) Continues To Be Hot This Week? 2022/08/31 19:00:00 Stocks Register
Hologic Inc. (NASDAQ:HOLX) traded at $67.10 at last check on Wednesday, August 31, made an upward move of 0.15% on its previous day’s price. Looking at the stock we see that its previous close was $67.00 and the beta (5Y monthly) reads 1.09 with the day’s price range being $66.44 – $67.56. The company has … Hologic Inc. (NASDAQ: HOLX) Continues To Be Hot This Week? Read More »
Hologic Continues To Offer Compelling Long-Term Value, Thesis Unchanged (NASDAQ:HOLX) 2022/08/29 19:14:01 Seeking Alpha
Hologic continues to display compelling long-term value with strong FCF generation and equally as high return on investment.
Global Medical Imaging Informatics Markets, 2021-2028 - Rising Demand for AI- and Cloud-Based Platforms & Technological Advancements in Medical Imaging Informatics - ResearchAndMarkets.com 2022/08/01 09:06:00 Kwhen Finance
Hologic''s Return On Capital Employed Overview 2022/07/28 15:47:20 Benzinga
Pulled from Benzinga Pro data, Hologic (NASDAQ: HOLX ) posted Q3 earnings of $228.40 million, an increase from Q2 of 49.88%. Sales dropped to $1.00 billion, a 30.15% decrease between quarters. Hologic earned $455.70 million, and sales totaled $1.44 billion in Q2. Why Is ROCE Significant? Earnings data without context is not clear and can be difficult to base trading decisions on. Return on Capital Employed (ROCE) helps to filter signal from noise by measuring yearly pre-tax profit relative to capital employed by a business. Generally, a higher ROCE suggests successful growth of a … Full story available on Benzinga.com
Hologic, Inc. (HOLX) CEO Stephen MacMillan on Q3 2022 Results - Earnings Call Transcript 2022/07/28 03:23:04 Seeking Alpha
Hologic, Inc. (NASDAQ:NASDAQ:HOLX) Q3 2022 Results Earnings Conference Call July 28, 2022, 04:30 PM ET Company Participants Ryan Simon - Vice President, Investor Relations Stephen MacMillan…